Compare Biogen Inc (BIIB) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Visa Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Visa Inc trades at $355.84 (market cap $677.06B). The key difference: Visa Inc is far larger — about 23.9× Biogen Inc's market cap, and Visa Inc pays a 0.75% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | V | |
|---|---|---|
Market Cap | $28.34B | $677.06B |
Sector | Health | Financials |
52-Week High | $216.63 | $362.13 |
52-Week Low | $122.68 | $295.52 |
Enterprise Value | $30.62B | $687.65B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Visa (V) trades at $357.75, up 2.52% today, near its pivot point of $357 with bullish technical signals and strong analyst consensus. The company reported Q1 2026 EPS of $3.31, beating estimates, and maintains robust profitability with a 51.68% net income margin. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $394.50, implying 10% upside, supported by earnings momentum and innovation in payment technology. Risks include competitive pressures from fintech and regulatory scrutiny, but institutional holdings and a debt-to-asset ratio of 25.26% reflect financial stability. The stock offers a compelling growth profile with manageable risks for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
